SA
VKTX icon

Scarborough Advisors’s Viking Therapeutics VKTX Stock Holding History

Scarborough Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10
Closed -$820 – 463
2024
Q1 		$820 Buy
+10
New +$445 ﹤0.01% 348

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Scarborough Advisors's VKTX Position: Q2 2024 in Review

Scarborough Advisors sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 10 shares — an estimated $820 sold.

Scarborough Advisors first reported a position in VKTX in Q1 2024 and held it in 1 quarter. The position peaked at $820 in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Scarborough Advisors reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Scarborough Advisors sold 10 Viking Therapeutics shares in Q2 2024, an estimated $820.
  • Scarborough Advisors first reported a position in Viking Therapeutics in Q1 2024 and held it in 1 quarter.
  • Scarborough Advisors's Viking Therapeutics position peaked at $820 in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Scarborough Advisors's 13F filing for Q2 2024, filed 8 Aug 2024.